“Investors saw opportunities in US biotech companies regardless of their size.”

So says EY’s annual global biotechnology report, Beyond Borders, which was just released coinciding with the BIO Convention starting in Philadelphia. The industry’s strong performance is shown in many areas of the report.

From the introduction/executive summary:

“This was a year for the record books. On almost every measure we track ― revenues, profitability, capital raised and more ― the industry reached new heights in 2014, spurred by a confluence of positive trends. Sustained sales of high-profile products continued to boost investor sentiment. Examples include Biogen’s Tecfidera and Gilead Science’s Hepatitis C medicines, Sovaldi and Harvoni, which quickly became two of the most successful product launches in the industry’s history.”

The Big 3

The San Francisco Bay Area, New England and San Diego again held the top spots in the report’s regional performance statistics. The comparison of the total revenue of companies and the net income of those companies:


The EY report is yet another resource (following the StartUp Health Insights report (digital health)  and the MoneyTree Life Sciences Report Quarterly Q1 2015 from PricewaterhouseCoopers) in 2015 that again shows the dominance of the “Big 3” regions.  This is also shown from BIO itself as the “Big 3” is part of a new schedule that rotates the convention between San Francisco (2016), San Diego (2017) and Boston (2018).

EY’s Beyond Borders Report

For more information about the report, click here.